GlassScriptPhysician profile
Sandhya Maradana
NPI 1154844462
$2,495.63
in general payments reported to CMS, 2019-2025
35 companies · $981 in 2025
The $981 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $73.07 · 2023: $291 · 2024: $889 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,160.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.09 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $191.72 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $156.74 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $152.75 | 2025 | Tepezza, Evenity, Prolia |
| Cequr Corporation | $143.96 | 2023-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $129.28 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $116.12 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $95.03 | 2019-2025 | |
| Insulet Corporation | $85.11 | 2023-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $79.81 | 2023-2025 | Isturisa, Signifor Lar |
| Pfizer INC. | $79.43 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $70.96 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $67.91 | 2023-2024 | Gvoke Hypopen |
| Dexcom, INC. | $63.49 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $61.99 | 2024-2025 | Freestyle Libre 3 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $61.53 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $60.49 | 2023-2025 | Strensiq |
| Boston Scientific Corporation | $30.92 | 2024 | |
| Ibsa Pharma INC. | $24.53 | 2024 | Licart, Tirosint |
| Sanofi-Aventis U.S. LLC | $24.10 | 2024 | |
| Medtronic, INC. | $23.94 | 2025 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $23.89 | 2025 | Imcivree |
| Viiv Healthcare Company | $23.72 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.07 | 2019 | |
| Corcept Therapeutics | $22.99 | 2024 | Korlym |
| Abbvie INC. | $22.91 | 2019 | |
| Beta Bionics, INC. | $21.11 | 2024 | Ilet Bionic Pancreas |
| Jazz Pharmaceuticals INC. | $18.92 | 2020 | |
| Alvogen INC | $18.69 | 2025 | Teriparatide |
| Shire North American Group INC | $18.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.18 | 2019 | |
| Sequel Med Tech, LLC | $17.09 | 2025 | Twiist |
| E.R. Squibb & Sons, L.L.C. | $16.85 | 2019 | |
| Kyowa Kirin, INC. | $13.54 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Maradana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.